Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience.
CDK4/6 inhibitors
Ki67
PR
advanced breast cancer
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
08 Aug 2020
08 Aug 2020
Historique:
received:
03
07
2020
revised:
06
08
2020
accepted:
08
08
2020
entrez:
14
8
2020
pubmed:
14
8
2020
medline:
14
8
2020
Statut:
epublish
Résumé
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of progesterone receptor (PR) and Ki67, assessed by immunohistochemistry, in 71 ABC patients treated with CDK4/6i and analyzed the impact of these markers on progression-free survival (PFS). The majority of patients 63/71 (88.7%) received palbociclib, 4 (5.6%) received ribociclib, and 4 (5.6%) received abemaciclib. A higher median value of Ki67 was observed in cases undergoing second-line treatment (
Identifiants
pubmed: 32784518
pii: diagnostics10080573
doi: 10.3390/diagnostics10080573
pmc: PMC7460222
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
J Clin Oncol. 2007 Nov 20;25(33):5287-312
pubmed: 17954709
Jpn J Clin Oncol. 2015 Dec;45(12):1097-102
pubmed: 26486823
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
J Pathol. 2002 Nov;198(3):292-9
pubmed: 12375261
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Nat Rev Mol Cell Biol. 2013 Aug;14(8):518-28
pubmed: 23877564
Sci Rep. 2017 Mar 27;7:45411
pubmed: 28345619
Eur J Cancer. 2018 Nov;104:21-31
pubmed: 30308388
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Lancet Oncol. 2020 Feb;21(2):250-260
pubmed: 31859246
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Oncotarget. 2017 Jul 4;8(27):43678-43691
pubmed: 28620137
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
Breast Cancer Res Treat. 2015 Jul;152(1):57-65
pubmed: 26012644
Clin Cancer Res. 2016 Apr 15;22(8):2000-8
pubmed: 26631614
Breast Cancer. 2018 Jul;25(4):479-488
pubmed: 29470723
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
NPJ Breast Cancer. 2018 Dec 18;4:41
pubmed: 30588487
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Breast Cancer Res Treat. 2009 Jul;116(1):53-68
pubmed: 18592370
Cell. 2004 Aug 20;118(4):493-504
pubmed: 15315761
J Clin Pathol. 1998 Nov;51(11):818-24
pubmed: 10193322
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Clin Cancer Res. 2015 Nov 1;21(21):4760-6
pubmed: 26324739